NDAOPHTHALMICSUSPENSION/DROPS
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC S is a topical ophthalmic suspension of betaxolol hydrochloride, a selective beta-1 adrenergic antagonist used to lower intraocular pressure in glaucoma and ocular hypertension. It is administered as eye drops and works by reducing aqueous humor production in the eye.
$0.675MPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with minimal Part D engagement; brand team focus likely shifting to generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
105 enrolled
GlaucomaOcular Hypertension
Career Relevance
BETOPTIC S offers limited career growth given its approaching loss of exclusivity and minimal linked job openings. Professionals joining this team should expect focus on defensive strategy, generic transition planning, and market access optimization rather than expansion.
Worked on BETOPTIC S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.